{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:46Z","timestamp":1791644806684,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jcjo.2024.03.021","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T04:07:52Z","timestamp":1713067672000},"page":"e510-e514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of topical 0.5% 5-Fluorouracil as primary treatment of ocular surface squamous neoplasia"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-4644","authenticated-orcid":false,"given":"Juliana Mika","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla Luppi","family":"Ballalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Picciarelli","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Miyuki","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2024.03.021_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.survophthal.2003.10.008","article-title":"Tumors of the conjunctiva and cornea","volume":"49","author":"Shields","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0002","first-page":"109","article-title":"conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes\u2014the 2017 J. Donald M. Gass Lecture","volume":"6","author":"Shields","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0003","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/tmi.12203","article-title":"Epidemiology of ocular surface squamous neoplasia in Africa","volume":"18","author":"Gichuhi","year":"2013","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0004","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00003495-200767020-00005","article-title":"The clinical applications of fluorouracil in ophthalmic practice","volume":"67","author":"Abraham","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0005","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","article-title":"Topical 5-Fluorouracil 1% as primary treatment for ocular surface squamous neoplasia","volume":"123","author":"Joag","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0006","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/bjophthalmol-2016-309219","article-title":"Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study","volume":"101","author":"Parrozzani","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ICO.0000000000001027","article-title":"Exfoliative cytology in the diagnosis of ocular surface squamous neoplasms","volume":"36","author":"Kayat","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2022.12.002","article-title":"Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study","volume":"27","author":"Wylegala","year":"2023","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0009","article-title":"A case of sight threatening complications from topical 1% 5-fluorouracil in the treatment of ocular surface squamous neoplasia","volume":"25","author":"Lin","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/ICU.0000000000000451","article-title":"Drop instillation and glaucoma","volume":"29","author":"Davis","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0011","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jtos.2015.02.001","article-title":"High-resolution optical coherence tomography as an adjunctive tool in the diagnosis of corneal and conjunctival pathology","volume":"13","author":"Nanji","year":"2015","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0012","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jtos.2022.12.009","article-title":"Long term study of topical interferon \u03b1-2b eye drops as primary treatment of ocular surface squamous neoplasia","volume":"28","author":"Sripawadkul","year":"2023","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0013","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","article-title":"Comparison of topical 5-Fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia","volume":"199","author":"Venkateswaran","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4103\/ijo.IJO_1665_20","article-title":"Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: Comparative analysis of outcomes based on original tumor configuration","volume":"69","author":"Shields","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ICO.0000000000001116","article-title":"Retrospective comparative study of topical interferon \u03b12b versus mitomycin C for primary ocular surface squamous neoplasia","volume":"36","author":"Kusumesh","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0016","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/bjo.2005.086850","article-title":"Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia","volume":"90","author":"Khong","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/IOP.0b013e3181ac4c39","article-title":"Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia","volume":"25","author":"Ballalai","year":"2009","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0018","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/bjo.2004.048033","article-title":"Epiphora as a side effect of topical mitomycin C","volume":"88","author":"Kopp","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0019","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exer.2014.10.015","article-title":"Pathophysiology of ocular surface squamous neoplasia","volume":"129","author":"Gichuhi","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2011.04.001","article-title":"Conjunctival squamous cell carcinoma arising in immunosuppressed patients (organ transplant, human immunodeficiency virus infection)","volume":"118","author":"Shields","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0021","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s40123-022-00535-6","article-title":"Topical chemotherapy for treating ocular surface squamous neoplasia with a combination of interferon \u03b1-2b and 5-Fluorouracil","volume":"11","author":"Geng","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jcjo.2024.03.021_bib0022","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1097\/IOP.0000000000000924","article-title":"Multifocal ocular surface squamous neoplasia","volume":"33","author":"Singh","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T17:51:21Z","timestamp":1726595481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418224001017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0008418224001017"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.03.021","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of topical 0.5% 5-Fluorouracil as primary treatment of ocular surface squamous neoplasia","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}